Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 May 19;18(1):224.
doi: 10.1186/s13063-017-1968-6.

BAlloon versus Stenting in severe Ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial

Benjamin D Hunt  1 , Matthew A Popplewell  2 , Huw Davies  2 , Lewis Meecham  2 , Hugh Jarrett  3 , Gareth Bate  2 , Margaret Grant  3 , Smitaa Patel  3 , Catherine Hewitt  3 , Lazaros Andronis  4 , Jonathan J Deeks  3 , Andrew Bradbury  2 ; BASIL-3 Collaborative Group
Affiliations
Randomized Controlled Trial

BAlloon versus Stenting in severe Ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial

Benjamin D Hunt et al. Trials. .

Abstract

Background: Severe limb ischaemia (SLI) is defined as the presence of rest pain and/or tissue loss secondary to lower extremity atherosclerotic peripheral arterial disease. The superficial femoral and popliteal arteries are the most commonly diseased vessels in such patients and are being increasingly treated using endovascular revascularisation techniques. However, it is currently unknown whether drug-eluting stents and drug-coated balloons confer additional clinical benefits over more established techniques using plain balloons and bare metal stents, or whether they represent a cost-effective use of NHS resources.

Methods: The BASIL-3 trial is a UK National Institute for Health Research, Health Technology Assessment Programme-funded, multicentre, randomised controlled trial (RCT) comparing the clinical and cost-effectiveness of plain balloon angioplasty with or without bail-out bare metal stenting, drug-coated balloon angioplasty with or without bail-out bare metal stenting, and primary stenting with drug-eluting stents for SLI secondary to femoro-popliteal disease. Patients with 'multilevel' disease may receive aorto-iliac and/or infrapopliteal treatments concurrently with their randomised femoro-popliteal intervention. The primary clinical outcome is amputation-free survival defined as the time to major (above the ankle) amputation of the index limb or death from any cause. The primary outcome for the economic analysis is cost per quality-adjusted life year. Secondary outcome measures include overall survival, major adverse limb events, major adverse cardiac events, relief of ischaemic pain, healing of tissue loss, and quality of life. The required sample size has been calculated at 861 participants (287 on each arm). These patients will be recruited over 3 years and followed-up for between 2 and 5 years.

Discussion: BASIL-3 is a pragmatic RCT designed to reflect current UK clinical practice. The results will inform decision-making regarding the appropriateness of funding the use of drug-coated balloons and drug-eluting stents, by the NHS, for the management of SLI due to femoro-popliteal disease.

Trial registration: ISRCTN Registry, identifier: ISRCTN14469736 . Registered on 22 October 2015.

Keywords: Angioplasty; Cost-effectiveness; Critical limb ischaemia; Diabetes; Drug-coated balloon; Drug-eluting stent; Endovascular treatment; Severe limb ischaemia; Stent.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of study design
Fig. 2
Fig. 2
Standard Protocol items: Recommendations for Interventional Trials (SPIRIT) diagram
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3(2):229–34. doi: 10.2147/vhrm.2007.3.2.229. - DOI - PMC - PubMed
    1. Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, Conte MS, Murad MH. The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015;62(6):1642–51. doi: 10.1016/j.jvs.2015.07.065. - DOI - PubMed
    1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Group TIW Inter-society consensus for the management of peripheral arterial disease (TASC II) J Vasc Surg. 2007;45 Suppl S:S5–67. doi: 10.1016/j.jvs.2006.12.037. - DOI - PubMed
    1. Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. J Vasc Surg. 2010;51(1):230–41. doi: 10.1016/j.jvs.2009.08.073. - DOI - PubMed
    1. National Institute for Health and Clinical Excellence. Lower limb peripheral arterial disease. Diagnosis and management. NICE clinical guideline 147. In: National Clinical Guideline Centre. 2012.

Publication types

MeSH terms

Associated data